Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $6.8750.

A number of research analysts recently commented on SRTS shares. Maxim Group lowered their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Alliance Global Partners assumed coverage on Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 target price for the company. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st.

Sensus Healthcare Stock Up 0.4%

SRTS opened at $2.70 on Wednesday. The firm has a 50-day simple moving average of $3.69 and a two-hundred day simple moving average of $4.07. Sensus Healthcare has a 52 week low of $2.66 and a 52 week high of $5.92. The company has a market capitalization of $44.44 million, a PE ratio of -5.74 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The firm had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

Institutional Trading of Sensus Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after buying an additional 3,766 shares in the last quarter. Pacific Ridge Capital Partners LLC raised its stake in Sensus Healthcare by 26.1% in the third quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company’s stock worth $1,800,000 after buying an additional 118,628 shares in the last quarter. Divisadero Street Capital Management LP raised its stake in Sensus Healthcare by 39.5% in the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock worth $1,422,000 after buying an additional 128,224 shares in the last quarter. Mindset Wealth Management LLC raised its stake in Sensus Healthcare by 28.1% in the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after buying an additional 11,000 shares in the last quarter. Finally, Opes Wealth Management LLC bought a new position in Sensus Healthcare in the third quarter worth approximately $50,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.